ArticleDiscover oncology2025
Unveiling the significance of ADAM12 through pan-cancer analysis and experimental verification in gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundADAM12, a member of the disintegrin and metalloproteinase family, has been involved in multiple cancers, yet its precise role in pan-cancer progression still remains elusive.
methodsIn our current study, we conducted a comprehensive analysis of ADAM12 expression, diagnosis, prognosis, genomic variations, DNA methylation, functional enrichment, immune infiltration as well as immunotherapy in pan-cancer utilizing public datasets. Additionally, a series of biological functional experiments of ADAM12 were performed in gastric cancer cells including cell counting kit-8 (CCK-8), colony formation, wound healing analysis, and Transwell analyses.
resultsADAM12 expression was prominently elevated and correlated with unfavorable prognosis in most cancer types. It exhibited elevated mutation frequency and a negative correlation with DNA methylation promoters across various tumors. ADAM12 expression strongly linked to ESTIMATE, immune/stromal scores, immune checkpoint genes, tumor mutation burden (TMB), and microsatellite instability (MSI) in specific cancer types. Single-cell and bulk RNA sequencing analysis revealed heightened ADAM12 levels in fibroblasts, highlighting its importance in tumor immunity. Furthermore, the predictive value of immunotherapy surpassed that of tumor mutational burden based on TIDE. Functional enrichment analysis associated ADAM12 with focal adhesion, PI3K-Akt signaling, and ECM-receptor interactions. In vitro experiments confirmed that ADAM12 downregulation significantly impeded proliferation, migration, and invasion of gastric cancer cells.
conclusionsADAM12 might be a valuable prognostic biomarker and a promising candidate for tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.